KRYSTAL BIOTECH INC (KRYS)
Health Care · Biotechnology · NASDAQ
Krystal Biotech is a commercial-stage gene therapy company using its proprietary STAR-D platform to treat rare diseases with targeted, redosable genetic medicines.
What KRYSTAL BIOTECH INC does
Krystal Biotech is a commercial-stage biotechnology company focused on the discovery, development, and commercialization of genetic medicines. The company utilizes a proprietary STAR-D (Skin TARgeted Delivery) platform to develop redosable gene therapies for patients with rare dermatological and respiratory diseases.
Themes: gene therapy, rare diseases, dermatology, respiratory medicine, genetic medicines
Fundamentals
- Price$346.58 as of 2026-08-21 close
- Market cap$10.3B as of 2026-08-21
- 1-year return+137.9% 2025-08-21 close $145.70 → 2026-08-21 close $346.58
- P/E40.23 as of 2026-08-24
- Net margin+54.8% as of 2026-08-24
- Gross margin+94.6% as of 2026-08-24
- ROE+19.3% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+22.6% as of 2026-08-24
- Beta0.48 as of 2026-08-24
- Last reported earnings2026-08-03 SEC EDGAR Form 8-K (Item 2.02)
How KRYS compares in its sector
- price-to-earnings ratiomiddle range 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 10% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 10% 504 covered Health Care peers, as of 2026-08-24
- gross margintop 10% 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 25% 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)top 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
KRYS is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
31.9 #1616 of 1,704 scored · #228 of 240 in Health Care
Momentum 54th: its RSI momentum gauge is in neutral territory; trend 52nd: the price is 6% above the average price paid over the period covered, so the typical buyer over that stretch is showing a gain; weakest is setup 25th: no fresh 20-day breakout up or down. Its score is docked 10 points for overextended (RSI above 75 or stochastic above 90).
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How KRYSTAL BIOTECH INC looks technically
KRYSTAL BIOTECH INC (KRYS) is trading 23.8% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 211 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 22 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 55, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive). It made a new 20-day low about 15 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 23.8% above its 200-day average, the long-term trend line — a longer-term uptrend | +23.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $345.35 | $345.35 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $280.00 | $280.00 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 18 calendar days ago — the swings before that are what the structure reading is measured on | 18 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 297.02. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 211 trading days ago — a "golden cross", a bullish long-term signal | 211 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 22 (a reading of 25+ marks a strong trend) | 21.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 55, neither overbought (above 70) nor oversold (below 30) | 54.6 |
|---|---|---|
| Position in its 14-day range | it is trading right at the top of its 14-day range ($313.75 to $348.03) — its "stochastic" reading is 96 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 95.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive) | 3 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $382.54 | $382.54 |
|---|---|---|
| From the 52-week high | it is 9.4% below its 52-week high (its highest price of the past year) | -9.4% |
| Above the 52-week low | it is 153.5% above its 52-week low (its lowest price of the past year) | +153.5% |
| Below the 52-week high | it is 9.4% below its highest point of the past year | 9.4% |
| Since a 20-day breakout | it made a new 20-day low about 15 trading days ago | 15 sessions |
| Since a 55-day breakout | it made a new 55-day high about 39 trading days ago | 39 sessions |
| All-time high | its highest closing price on record is $382.54 (set on 2026-06-30) | $382.54 |
| Given back of the 52-week move | over the past year its closes ranged ($137.46 to $378.15), and it has given back only a small part of its rise from last year’s low — 13% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $221.70 to $229.40. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 13.1% |
| From the all-time high | it is 9.4% below its all-time high | -9.4% |
| Nearest price level | it is trading 8.4% above a support level at $317.53 — a price it turned at twice since 2026-05-14, most recently on 2026-05-29. Since 2024-08-21 it has 17 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -8.4% |
| All-time low | its lowest closing price on record is $8.03 (set on 2017-12-19) | $8.03 |
| Above the all-time low | it is 4216.1% above its all-time low | +4,216% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 63rd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $12.95 between its high and its low — about 3.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $12.95 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $308.59 and $366.13 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $308.59 – $337.36 – $366.13 |
| Typical daily range (% of price) | its price moves about 3.7% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.7% |
| Stretch from the 200-day average | it is trading 5.1 daily ranges above its 200-day average price (23.8% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 5.1 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.82× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 0.6% since the prior reading | +0.6% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has softened toward "sell" since the prior reading | 0.07 toward sell |
Candlestick patterns
2
| Since a doji | 3 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 3 sessions ago |
|---|---|---|
| Since a bullish engulfing | 4 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 4 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.1% |
|---|---|---|
| Open gap | it gapped 2.0% above the previous close 2 sessions ago and has not traded back through the level it left behind at 332.82 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.0% |
| Gap filled | a 6.0% gap down opened on 2026-08-03 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it took 12 sessions to close | 2 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 0.1 percentage points (the stock gained 2.2% while the market gained 2.3%) | -0.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 10.8 percentage points (the stock gained 13.9% while the market gained 3.1%) | +10.8% |
| vs market, 6 months | over the past 6 months this stock beat the market by 21.3 percentage points (the stock gained 32.4% while the market gained 11.1%) | +21.3% |
| vs market, 12 months | over the past 12 months this stock beat the market by 117.4 percentage points (the stock gained 137.9% while the market gained 20.5%) | +117.4% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 8.9% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 14% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $303.71 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +14.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 6% above the average price paid since it last reported on 2026-08-03 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $326.76 — a volume-weighted average of daily closes over 15 sessions, not a true tick-by-tick VWAP. | +6.1% |
Price levels it has turned at before
KRYS last closed at $346.58 on 2026-08-21. Since 2024-08-21 it has turned at 17 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $317.53 | Support | 8.4% below the last close | turned there twice · 2026-05-14 to 2026-05-29 |
| $382.33 | Resistance | 10.3% above the last close | turned there twice · 2026-06-30 to 2026-07-09 |
| $297.10 | Support | 14.3% below the last close | turned there three times · 2026-01-14 to 2026-08-03 |
| $285.86 | Support | 17.5% below the last close | turned there three times · 2026-02-03 to 2026-06-02 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $297.02.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · MACD just crossed bullish (12/26/9) · beating the market · Just filled a gap (5%+ closed in the last week) · At the top of its 14-day range (stochastic above 80) · Trading inside the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.27 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
- Mean price target$385.00 range $284.00 – $474.00; median $389.00
Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for KRYS
- Consensus EPS estimate$2.00 next reporting period, as of 2026-08-22
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on the success of a limited number of product candidates.","Potential for significant fluctuations in operating results and profitability.","Risks associated with the manufacturing, supply chain, and regulatory approval of gene therapy products."]
What changed in the latest 10-Q
AI-assisted comparison of KRYS's 10-Q filed 2026-05-04 against the prior one filed 2025-11-03.
Management's Discussion & Analysis (MD&A)
- Added:
- Added reference to 2025 10-K filed February 17, 2026 (newer filing, 2026-05-04)
- Added statement that both EU and Japan approvals in 2025 include flexible dosing options with potential for patient or caregiver administration in home setting (newer filing)
- Added specific launch dates: Germany in August 2025, France and Japan in October 2025 (newer filing)
- Added statement that France launch is under post-marketing authorization early reimbursed access Accès Précoce program (newer filing)
- Added pricing negotiation timeline details: expected to continue until second half of 2026 in Germany and 2027 in France (newer filing)
- Added statement that pricing negotiations were successfully completed in Japan prior to launch (newer filing)
- Added statement about advancing pricing discussions with Italian and Spanish reimbursement authorities for potential launches in second half of 2026 (newer filing)
- Removed:
- Removed reference to 2024 10-K filed February 19, 2025 (older filing, 2025-11-03)
- Removed full name expansion 'herpes simplex virus-1 (HSV-1)' in favor of abbreviated 'engineered HSV-1' (newer filing simplifies)
- Removed full name expansion 'Current Good Manufacturing Practice (CGMP)' in favor of 'CGMP' only (newer filing simplifies)
- Removed parenthetical note 'referred to as B-VEC outside the U.S., Europe, and Japan' from product name (newer filing)
- Removed description of VYJUVEK as 'the first ever redosable gene therapy' (older filing, 2025-11-03)
- Removed phrase 'earlier this year' when referring to Japan and Europe approvals (older filing, 2025-11-03)
- Removed detailed description of EC April 2025 marketing authorization specifics (text truncated in older filing)
- Removed bullet point about plans and expected timing of commercial launches in Europe outside Germany and France (older filing)
- Removed bullet point about plans for commercialization outside U.S., major European markets, and Japan (older filing)
- Removed bullet point about expectations regarding revenue and expenses categories (older filing)
- Removed bullet point about plans to identify, develop and commercialize product candidates (older filing)
- Removed bullet point about business model and strategic plans (older filing)
- Removed phrase 'Given these uncertainties, you should not place undue reliance on these forward-looking statements' (older filing)
- Reworded:
- Changed 'appearing in a number of places throughout this Quarterly Report' to 'appearing in this Quarterly Report' (newer filing, 2026-05-04)
- Changed reference from 'Item 1A of Part II' to 'Part I, Item 1A of our Annual Report on Form 10-K' for risk factors (newer filing)
- Changed word order from 'fully integrated, commercial-stage, global' to 'fully integrated, global, commercial-stage' (newer filing)
- Changed 'Europe' to 'European Union (EU)' in product approval statement (newer filing)
- Changed 'approved in Japan and Europe earlier this year' to specific dates: 'approved in Japan and the EU in 2025' (newer filing)
- Notes:
- Older filing text appears truncated at end of Overview section, limiting full comparison
- Comparison covers forward-looking statements section and Overview section only due to text truncation in older filing
Risk Factors
- Added:
- Newer filing (2026-05-04) reports Q1 2026 financial statements with balance sheet as of March 31, 2026 and December 31, 2025
- Newer filing includes three-month period ended March 31, 2026 in statements of operations
- Newer filing reports stockholders' equity statement for three-month period ended March 31, 2026
- Newer filing includes cash flow statement for three-month period ended March 31, 2026
- Newer filing reports Q1 2026 product revenue of $116,357 thousand compared to Q1 2025 revenue of $88,183 thousand
- Newer filing reports Q1 2026 net income of $55,932 thousand versus Q1 2025 net income of $35,733 thousand
- Removed:
- Older filing (2025-11-03) contained nine-month ended September 30, 2025 and 2024 comparative statements
- Older filing reported accumulated deficit of $(27,237) thousand as of September 30, 2025 and $(180,668) thousand as of December 31, 2024
- Older filing included litigation settlement expense of $12,500 thousand in Q3 2024 operations
- Older filing reported nine-month 2025 net income of $153,431 thousand
- Older filing included deferred income tax benefit of $24,680 thousand in nine-month operating activities
- Reworded:
- Accumulated deficit in older filing changed to Retained earnings in newer filing (balance sheet presentation)
- Older filing reported 'Accumulated other comprehensive gain (loss)' while newer filing reports 'Accumulated other comprehensive (loss) gain' (different parenthetical ordering)
- Cash flow statement line item changed from 'Amortization (accretion) on marketable securities' in older filing to 'Accretion on marketable securities' in newer filing
- Notes:
- The two filings cover different reporting periods: newer filing is Q1 2026 (three months) while older filing is nine months ended September 30, 2025; direct period-to-period comparisons are limited
- Balance sheet dates differ: newer filing shows March 31, 2026 versus December 31, 2025; older filing shows September 30, 2025 versus December 31, 2024
- Risk Factors section page number changed from 32 in older filing to 26 in newer filing, suggesting content reorganization but detailed Risk Factors text not provided for comparison
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 23 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 23 sells ($16M) — 3 selling insiders
- Last 180 days0 buys · 47 sells ($33M) — 5 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-25. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about KRYS's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
6 institutional 13F filers reported holding KRYS as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 9,716,970
- Reported value $2,510,087,621
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
KRYS had 3,202,260 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
KRYS had 10.8% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.15 days to cover at the same settlement.
- Reported short interest (shares) 3,202,260
- Short interest (% of shares outstanding) 10.8%
- Prior settlement (shares) 3,496,648
- Reported change -8.42%
- Days to cover (reported) 4.15
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Amryt Pharma
- Castle Creek Biosciences
- BridgeBio Pharma (BBIO)
- Regeneron Pharmaceuticals (REGN)
- Vertex Pharmaceuticals (VRTX)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare KRYS vs…
KRYSTAL BIOTECH INC is found in…
Frequently asked questions
What does KRYSTAL BIOTECH INC (KRYS) do?
Krystal Biotech is a commercial-stage biotechnology company focused on the discovery, development, and commercialization of genetic medicines. The company utilizes a proprietary STAR-D (Skin TARgeted Delivery) platform to develop redosable gene therapies for patients with rare dermatological and respiratory diseases.
What sector is KRYSTAL BIOTECH INC (KRYS) in?
KRYSTAL BIOTECH INC (KRYS) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are KRYSTAL BIOTECH INC's (KRYS) competitors?
Notable peers of KRYSTAL BIOTECH INC (KRYS) include Amryt Pharma, Castle Creek Biosciences, BridgeBio Pharma, Regeneron Pharmaceuticals and Vertex Pharmaceuticals. This peer set is informational only — not financial advice.
Is KRYSTAL BIOTECH INC (KRYS) overbought or oversold right now?
KRYSTAL BIOTECH INC (KRYS) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 55, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on KRYS come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.